Page 1

Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019 GlobalData, the industry analysis specialist, has released its new report, “Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019�. The report is an essential source of information and analysis on the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The report identifies the key trends shaping and driving the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Post-Traumatic Stress Disorder (PTSD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Get more information of this report @ http://www.reportsnreports.com/reports/167924posttraumatic-stress-disorder-therapeutics-ptsd-pipeline-assessment-and-market-forecasts-to2019.html Report Details: Published: June 2012 No. of Pages: 87 Price: Single User License: US $ 3995

Corporate User License: US $ 11985

Scope The report provides information on the key drivers and challenges of the Post-Traumatic Stress Disorder (PTSD) Therapeutics market. Its scope includes - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Post-Traumatic Stress Disorder (PTSD) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. - Analysis of the current and future competition in the seven key countries Post-Traumatic Stress Disorder (PTSD) Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Post-Traumatic Stress Disorder (PTSD) Therapeutics market. - Analysis of key recent licensing and partnership agreements in Post-Traumatic Stress Disorder (PTSD) Therapeutics market

Reasons to buy The report will enhance your decision making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of


pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What’s the next big thing in the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market landscape? – Identify, understand and capitalize. Major points covered in Table of Contents of this report include: Table of Contents 1 Table of Contents 3 1.1 List of Tables 5 1.2 List of Figures 6 2 Posttraumatic Stress Disorder Therapeutics - Introduction 8 2.1 Disease Overview 8 2.2 Epidemiology 9 2.2.1 Prevalence 9 2.2.2 Pharmacoeconomic Burden 11 2.2.3 Quality of Life (QoL) 12 2.3 Etiology and Pathophysiology 12 2.3.2 Risk Factor 18 2.3.3 Co-morbidities 19 2.4 Signs and Symptoms 20 2.4.1 Re-experiencing Symptoms 20 2.4.2 Avoidance symptoms 20 2.4.3 Hyperarousal Symptoms 20 2.5 Diagnosis 22 2.5.1 Diagnosis Criteria 22 2.5.2 Psychobiologic Approaches 25 2.6 Treatment and Management Options 26 2.6.1 Non-pharmacological Treatment 28 2.6.2 Pharmacological Treatment 28 2.6.3 The US 31 2.6.4 Europe 32 2.7 Referral Pathway 33 2.8 GlobalData Pipeline Report Guidance 34 3 Posttraumatic Stress Disorder Therapeutics - Market Characterization 35


3.1 Overview 35 3.2 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Global 35 3.3 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Global 37 3.4 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - The US 38 3.5 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - The US 39 3.6 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - France 40 3.7 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - France 41 3.8 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Germany 42 3.9 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Germany 43 3.10 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Italy 44 3.11 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Italy 45 3.12 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Spain 46 3.13 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Spain 47 3.14 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - The UK 48 3.15 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - The UK 49 3.16 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Japan 50 3.17 PTSD Therapeutics Market Forecast (2011-2019) - Japan 51 3.18 Drivers and Barriers for the Posttraumatic Stress Disorder Therapeutics Market 52 3.18.1 Drivers for the Posttraumatic Stress Disorder Therapeutics Market 52 3.18.2 Barriers for the Posttraumatic Stress Disorder Therapeutics Market 52 3.19 Opportunity and Unmet Need Analysis 53 3.20 Key Takeaway 54 4 Posttraumatic Stress Disorder Therapeutics - Competitive Assessment 55 4.1 Overview 55 4.2 Strategic Competitor Assessment 55 4.3 Product Profiles for the Major Marketed Products in the Posttraumatic Stress Disorder Therapeutics Market 56 4.3.1 Selective Serotonin Reuptake Inhibitors (SSRIs) 56 4.3.2 Paxil (paroxetine) 57 4.3.3 Zoloft (sertraline) 58 4.3.4 Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) 59 4.3.5 Atypical Antipsychotics 60 4.4 Key Takeaway 60 5 Posttraumatic Stress Disorder Therapeutics - Pipeline Assessment 61 5.1 Overview 61 5.2 Strategic Pipeline Assessment 61 5.3 Posttraumatic Stress Disorder Therapeutics Pipeline - Pipeline by Phases of Development 62 5.3.1 Posttraumatic Stress Disorder Therapeutics - Phase III Pipeline 62 5.3.2 Posttraumatic Stress Disorder Therapeutics - Phase II Pipeline 63 5.3.3 Posttraumatic Stress Disorder Therapeutics - Phase I Pipeline 63 5.3.4 Posttraumatic Stress Disorder Therapeutics - Pre-clinical Pipeline 63 5.3.5 Posttraumatic Stress Disorder Therapeutics - Discovery Pipeline 64 5.3.6 Technology Trends Analytic Framework 64 5.4 Posttraumatic Stress Disorder Therapeutics Market -Pipeline by Mechanism of Action 66 5.5 Molecule Profile for Promising Drugs under Clinical Development 67 5.5.1 Avlocardyl (propranolol) 67 5.6 Key Takeaway 67 6 Posttraumatic Stress Disorder Therapeutics - Clinical Trials Mapping 68 6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 68


6.2 Clinical Trials by Phase 69 6.3 Clinical Trials by Trial Status 70 6.4 Prominent Sponsors 71 6.5 Top Companies Participating in Posttraumatic Stress Disorder Therapeutics Clinical Trials 72 7 Posttraumatic Stress Disorder Therapeutics - Strategic Assessment 73 7.1 Key Events Impacting the Future Market 73 7.2 Posttraumatic Stress Disorder Therapeutics: Implications for Future Market Competition 74 8 Posttraumatic Stress Disorder Therapeutics - Future Players 75 8.1 Introduction 75 8.2 Company Profiles 76 8.2.1 Synosia Therapeutics/Biotie Therapies Corp. 76 8.2.2 Columbia Northwest Pharmaceuticals 77 8.2.3 Marinus Pharmaceuticals, Inc. 77 8.2.4 Nanotherapeutics, Inc. 78 9 Posttraumatic Stress Disorder Therapeutics - Licensing and Partnership Deals 79 10 Posttraumatic Stress Disorder Therapeutics - Appendix 80 10.1 Market Definitions 80 10.2 Abbreviations 80 10.3 Bibliography 81 10.4 Research Methodology 83 10.4.1 Coverage 83 10.4.2 Secondary Research 84 10.4.3 Forecasting 84 10.4.4 Primary Research 86 10.4.5 Expert Panel Validation 87 10.5 Contact Us 87 10.6 Disclaimer 87

Related Reports @ http://www.reportsnreports.com/publisher/globaldata/ Contact: TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252. Tel: + 1 888 391 5441 sales@reportsandreports.com Connect With Us:

Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019  

the industry analysis specialist, has released its new report, “Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and...

Read more
Read more
Similar to
Popular now
Just for you